

1 Identification of rare missense variants reducing cathepsin O 2 secretion in families with intracranial aneurysm

3
4 Milène Freneau^{1,*}, Raphael Blanchet^{1,*}, Sandro Benichi¹, Mary-Adel Mrad¹, Surya Prakash
5 Rao Batta¹, Marc Rio¹, Stéphanie Bonnaud¹, Pierre Lindenbaum¹, Fabien Laporte¹, Stéphane
6 Cuénot², Thibaud Quillard¹, Sandrine Morel^{3,4}, Brenda R. Kwak³, Philippe Bijlenga⁴, Jean-
7 François Deleuze⁵, Christian Dina¹, Maxence Bodet¹, Stéphanie Chatel¹, Emmanuelle
8 Bourcereau⁶, Solène Jouan⁶, Arturo Consoli⁷, Cyril Dargazanli⁸, Julien Ognard⁹, ICAN Study
9 Group, Hubert Desal^{1,6}, Anne-Clémence Vion¹, Romain Bourcier^{1,6,*}, Gervaise Loirand^{1,*,#},
10 Richard Redon^{1,*,#}.

11
12 ¹ Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes,
13 France

14 ² Nantes Université, CNRS, Institut des Matériaux de Nantes Jean Rouxel, IMN, F-44000
15 Nantes, France

16 ³ Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, CH-
17 1211 Geneva, Switzerland

18 ⁴ Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva
19 University Hospitals and University of Geneva, Geneva, Switzerland.

20 ⁵ Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine
21 (CNRGH), F-91057 Evry, France

22 ⁶ Department of Neuroradiology, CHU Nantes, F-44000 Nantes, France

23 ⁷ Department of Interventional Neuroradiology, Foch Hospital, University Versailles Saint-
24 Quentin en Yvelines, F-92073 Suresnes, France

25 ⁸ Department of Neuroradiology, University Hospital Centre Montpellier, F-34000 Montpellier,
26 France

27 ⁹ Radiology Department, University Hospital, F-29000 Brest, France

28 * These authors contributed equally to this work as first and last authors

29
30 #Correspondence: Gervaise Loirand, UMR Inserm 1087/Cnrs 6291, IRS–UN, 8 Quai
31 Moncoussu, BP 70721, 44007 Nantes cedex 1, France. Phone: 33 2 28 08 01 16; Email:
32 gervaise.loirand@univ-nantes.fr). Or to: Richard Redon, UMR Inserm 1087/Cnrs 6291, IRS–
33 UN, 8 Quai Moncoussu, BP 70721, 44007 Nantes cedex 1, France. Phone: 33 2 28 08 01 10;
34 Email: (richard.redon@univ-nantes.fr)

35
36 **Short title:** *CTSO* and intracranial aneurysm

37 **Conflict of interest statement:** The authors have declared that no conflict of interest exists.

38
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

39 **ABSTRACT**

40 Intracranial aneurysm (IA) is a common cerebrovascular abnormality characterized by
41 localized dilation and wall thinning in intracranial arteries, which can rupture and lead to fatal
42 subarachnoid hemorrhage. Although the pathophysiology of IA remains largely unknown,
43 increasing evidence suggests that genetic susceptibility plays a predominant role. Here, we
44 combined whole exome sequencing and identity-by-descent analyses with functional
45 investigations to identify rare functional variants associated to IA in families with multiple
46 affected subjects. We identified two rare missense variants in the *CTSO* gene in two large
47 pedigrees. We found that the cysteine-type papain-like cathepsin O (CTSO) encoded by
48 *CTSO* is expressed in the wall of human IA domes. Stretching of vascular smooth muscle
49 cells (VSMC) induced secretion of CTSO, which acted as an extracellular protease controlling
50 VSMC migration and adhesion to the extracellular matrix. CTSO depletion, as well as
51 expression of the two CTSO variants, which are poorly secreted, increased the amount of
52 fibronectin. In addition, CTSO depletion increased VSMC stiffness, which was reduced by
53 the addition of exogenous CTSO. Collectively, our findings identify CTSO as a potential new
54 player in arterial remodeling, regulating fibronectin deposition and VSMC function,
55 supporting the causal role of rare coding *CTSO* variants in familial forms of IA.
56

57 INTRODUCTION

58 Intracranial aneurysm (IA) is a generally asymptomatic localized dilation associated with
59 thinning and structural defects of the intracranial arterial wall affecting 1-5% of the general
60 population (1). The main risk of IA is its unpredictable rupture, responsible for ~36,000 of
61 subarachnoid hemorrhage cases per year in Europe and a major cause of sudden death in
62 "young healthy" subjects, in particular in women (peak of age: 50-60 years) (2, 3). Although
63 hypertension, ageing, female sex, smoking, excessive alcohol consumption and family history
64 of IA have been identified as risk factors predisposing to IA, the mechanisms underlying IA
65 formation, growth and rupture are mostly unknown. However, local hemodynamic constraints
66 of shear stress and pressure are assumed to play a key role (4). The aggregation of patients in
67 IA families suggests that genetic factors contribute to disease susceptibility, and identifying
68 these factors might be beneficial for at-risk patients before IA rupture (5, 6). Genome-wide
69 association studies have identified several common risk loci associated with IA (7-10).
70 However, the identification of specific genes or causal molecular pathways remains largely
71 inconclusive and these common alleles together only explain a small fraction of the risk
72 attributable to genetics for IA in the general population. On the other hand, whole-exome
73 sequencing (WES) has the potential to detect rare coding variants that have large effect and
74 induce a high risk of developing IA. Identifying such variants also could provide valuable
75 insights into IA pathophysiology and pave the way for new diagnostic or therapeutic
76 strategies. Indeed, recent studies have demonstrated the usefulness of familial approaches
77 based on WES to improve knowledge on the molecular mechanisms underlying IA formation
78 and rupture from the discovery of rare predisposing variants such as *RNF213* (11), *THSD1*
79 (12), *LOXL2* (13), *PCNT* (14), *ARHGEF17* (15), *ANGPTL6* (16), and *PPIL4* (17).
80 In the present study, by combining WES and identity-by-descent (IBD) analysis, we identified
81 rare coding variants in the Cathepsin O gene (*CTSO* [MIM: 600550]) in two familial cases of

82 IA. *CTSO* is one of the 11 cysteine-type papain-like cathepsins identified in humans about
83 which almost nothing is known (18). Our functional analysis revealed that *CTSO* controls
84 vascular smooth muscle cell (VSMC) migration and adhesion to the extracellular matrix
85 (ECM). Furthermore, *CTSO* depletion increased VSMC stiffness. These findings suggest that
86 the increased susceptibility to IA induced by *CTSO* variants is likely related to their primary
87 effects on vascular tissue, and more particularly on the media layer of the wall of cerebral
88 arteries.

89

90 **RESULTS**

91 **Identification of one rare coding variant affecting *CTSO* in a familial case of IA**

92 We first recruited a large family (pedigrees are available on request) with 6 definite carriers of
93 IA in two generations, among whom two had a history of IA rupture. In this family, there were
94 also 4 relatives with suspected IA (3 because of unexplained sudden death and 1 with a doubtful
95 ectasia on MRI, see Figure S1A), 3 individuals with unknown phenotypes in the absence of
96 MRI screening, and 19 subjects without IA detected on MRI. Among the definite carriers of
97 IA, all were females and 3 were carriers of multiple IA (with a maximum of 4 IAs detected for
98 1 subject). Of the twelve IAs detected in the family, 6 were located in the MCA territory (50%),
99 3 in the ACA (25%), 2 in the PCA (16%), and 1 in the ICA territory (9%) (Figure 1A and B).
100 The median maximal diameter of IA was 4 mm (min 3 mm, max 8 mm). We applied whole-
101 exome sequencing to 3 affected members of the family. Out of the 77 to 107 rare non-
102 synonymous or splicing variants detected in each 3 whole exomes, we found that only 8 were
103 shared between the 3 affected relatives (Table S1 and S2). IBD analysis on all available relatives
104 revealed that only one of the 8 variants resides within a shared haplotype - located at 4q32 -
105 between the 6 affected subjects (Table S1 and S3). We then confirmed this finding by capillary
106 sequencing. This missense variant in the *CTSO* gene - *CTSO* c.946G>A (p.Val316Ile) - is

107 reported with a Genomic Evolutionary Rate Profiling (GERP) score of 5.68 and predicted *in*
108 *silico* as damaging for CTSO protein structure and function by both PolyPhen-2 and SIFT
109 (Table 1).

110

111 **A second familial case of IA associated with rare *CTSO* coding variant**

112 To further investigate the putative involvement of *CTSO* in IA susceptibility, we then screened
113 for rare functional variants within this gene among 93 additional index cases with familial forms
114 of IA, for which WES data were available in-house. We found one additional rare missense
115 variant, *CTSO* c.128C>T (p.Ala43Val), in one case (Table 1). The corresponding family
116 comprised 4 IA carriers (3 females and 1 males), among whom one carried 2 IAs. The median
117 maximal diameter of IA was 5 mm (min 4 mm, max 9 mm). Three IAs were located in the
118 MCA territory, one in the ACA and one in the ICA territory, while in one case the location was
119 undetermined. undetermined. By capillary sequencing, we tested the *CTSO* c.128C>T variant
120 among family members and detected it in the 3 tested IA carriers but in none of their 6 non-
121 affected relatives (including a subject with uncertain phenotype, Figure S1B). This variant,
122 reported with a GERP score of 3.67, was predicted *in silico* as damaging by PolyPhen-2 but not
123 by SIFT (Table 1).

124

125 **Clinical characteristics and exposition to risk factors according to *CTSO* status**

126 When comparing subgroups of individuals with or without *CTSO* variant and carrying or not
127 IA among the two families members, we observed a higher proportion of subjects with history
128 of high blood pressure among the IA carriers ($p=0.013$) while we found no significant
129 differences regarding age, proportion of women, smoking habits, history of ischaemic stroke,
130 level of alcohol consumption, history of diabetes or dyslipidaemia, treatment with statin,
131 antiplatelet, oral anticoagulant and anti-inflammatory medication (Table 2).

132

133 **CTSO is expressed in cerebral arteries**

134 To explore the putative implication of CTSO in IA pathophysiology, we first sought to
135 investigate the expression of CTSO in cerebral arteries. *Ctso* mRNA was found at a similar
136 level in cerebral arteries of WKY rats and in arteries from spontaneously hypertensive rat
137 (SHR) and stroke prone SHR (SPSHR), suggesting that *Ctso* mRNA expression was not
138 modulated by high blood pressure (Figure 2A). In cultured cells, *Ctso* mRNA was expressed
139 in VSMC (Figure 2B) and, at weaker levels, in endothelial cells, where it was not affected by
140 shear stress (SS) (Figure 2C, D). In VSMC, CTSO was found in cell lysates but also in the
141 culture medium, indicating the secretion of the protein (Figure 2E). Moreover, CTSO
142 secretion was potentiated by stretch, without any change in mRNA level (Figure 2B and
143 Figure 2E). Interestingly, CTSO is expressed in the arterial wall of human IA domes (Figure
144 3A). In unruptured IA, CTSO was expressed in some endothelial cells and VSMC, but CTSO
145 staining was not observed in ECM. A significantly higher content of CTSO, particularly in the
146 ECM was detected in the arterial wall of ruptured IA thus confirming CTSO secretion in the
147 extracellular space by VSMC observed *in vitro*, particularly under stretching condition
148 (Figure 3B).

149

150 ***Ctso* silencing does not affect VSMC proliferation and apoptosis**

151 We next aimed to elucidate the role of CTSO in the arterial wall by focusing on VSMC, in
152 which it is predominantly expressed and its secretion is modulated by stretch. To this end, we
153 evaluated the consequences of siRNA-mediated knockdown of endogenous CTSO in VSMC
154 (KD-SMC) in comparison with a control siRNA pool (Cont-SMC). *Ctso* silencing did not
155 affect VSMC proliferation (Figure 4A), nor apoptosis as measured by TUNEL and caspase 3
156 cleavage in basal condition (no apoptosis, data not shown) and after induction of apoptosis by

157 staurosporine (Figure 4B and C). These results indicate that CTSO did not affect VSMC
158 proliferation and viability.

159

160 ***Ctso* silencing modifies VSMC migration and adhesion**

161 We next tested whether CTSO regulates the migratory and adhesive properties of VSMC
162 using Boyden chambers and adhesion assays, respectively. CTSO depletion in VSMC led to a
163 significant decrease in transmigration (Figure 4D), but accelerated the adhesion speed of
164 VSMC on fibronectin (FN) matrix (Figure 4E). This effect was associated with an increased
165 phosphorylation of focal adhesion kinase (FAK) in KD-SMC compared to cont-SMC, both at
166 2 h and 24 h after seeding on FN matrix (Figure 5A). When VSMC were plated on plastic,
167 without FN coating, a significant increase in FAK phosphorylation was also observed at 24 h
168 but not at 2 h post-seeding (Figure 5B). It is known that VSMC produce and release FN
169 which, in turn, can modulate their phenotype and functions (19). The observed differences in
170 FAK phosphorylation induced by CTSO depletion may therefore results from an effect on the
171 endogenous FN. To test this hypothesis, we thus analyzed the effect of *Ctso* silencing on FN
172 expression in Cont- and KD-SMC cultures. Western blot analysis revealed an increased level
173 of FN in KD-SMC compared to Cont-SMC, while there was no difference in collagen I
174 (COL-I) expression (Figure 5C). This rise in FN expression in KD-SMC was not associated
175 with a change in mRNA-*Fnl* level which, like mRNA-*Colla*, remains the same in Cont- and
176 KD-SMC (Figure5D). The observed increase in FN level induced by CTSO silencing could
177 therefore stem from the ability of CTSO to degrade FN. To test this hypothesis, we cultured
178 Cont- and KD-SMC on human FN, which we quantified by immunofluorescent labeling.
179 FN labelling confirmed the presence of a greater amount of FN in the vicinity of KD-SMC
180 compared to Cont-SMC (Figure 5E). All together, these data show that CTSO controls VSMC
181 migration and adhesion, and suggest that it could result from an effect on FN.

182

183 ***Ctso* silencing affects contractile phenotype marker gene expression**

184 We next assessed the potential role of CTSO on VSMC phenotype by measuring the
185 expression of contractile marker gene expression (Figure 6A). Compared with Cont-SMC, the
186 expression of all tested VSMC marker mRNAs, namely *Acta2*, *Myh11*, *Tagln* and *Cnn1* was
187 significantly up-regulated in KD-SMC, which showed a 90%-decrease in *Ctso* mRNA
188 expression (Figure 6B). By contrast, the expression of *Bmp4*, a known marker of osteogenic
189 differentiation of VSMC (20) was reduced in KD-SMC compared to Cont-SMC (Figure 6B).
190 These results suggest that *Ctso* silencing reinforced VSMC contractile phenotype. However,
191 measurement of contractility showed that KD-SMC contracted collagen gel less strongly than
192 Cont-SMC in response to the thromboxane A2 analog U46619 (Figure 6C).

193

194 ***Ctso* silencing induces stiffening of VSMC**

195 We then used atomic force microscopy (AFM) to assess the effect of CTSO depletion on
196 VSMC and VSCM-derived ECM stiffness, as arterial stiffening is known to be a risk factor
197 for IA (21). Elastic modulus determined by AFM nanoindentation showed that the stiffness of
198 KD-SMC was significantly higher than that of Cont-SMC, and was strongly reduced by
199 complementation with exogenous CTSO (Figure 7A and S2). In contrast, the corresponding
200 ECM produced by KD- and Cont-SMC displayed a similar stiffness (Figure 7A and S2).

201

202 **CTSO variants**

203 To assess the impact of c.128C>T *CTSO* and c.946G>A *CTSO* variants on CTSO protein we
204 established stable cell lines expressing wild-type (WT-CSTO), and the two mutated proteins,
205 p.Val316Ile-CTSO and p.Ala43Val-CTSO. Western blot analysis showed that expression
206 level in cell lysates was similar for WT-CTSO and the two mutated CTSO proteins (Figure

207 7B). In contrast, the amount of p.Val316Ile-CTSO and p.Ala43Val-CTSO in the culture
208 medium was strongly reduced compared to WT-CTSO (Figure 7B). Since we observed an
209 increase in the amount of FN after CTSSO depletion in VSMC (Figure 5C), we investigated the
210 effect of p.Val316Ile-CTSSO and p.Ala43Val-CTSSO expression on FN level. Western-blot
211 results show that the expression of CTSSO mutants mimicked the effect of CTSSO depletion on
212 the increase of FN level, without affecting COL-I expression (Figure 7C).

213

214 **Discussion**

215 We have identified two rare missense variants in the *CTSSO* gene shared by all the affected
216 relatives in two large pedigrees with multiple IA-affected relative. Of note, we also observed
217 several subjects (n=8) carrying possibly deleterious *CTSSO* variations but without IA at the
218 time of the study. In addition, we found a significant increase in the proportion of subjects
219 with history of high blood pressure among IA carriers compared to unaffected individuals.
220 High blood pressure history is a well-established environmental factor associated with the
221 development of IA (22). Our results suggest, as described previously in familial cases with
222 rare coding variants in *ANGPTL6*,(16) that rare coding variants in *CTSSO* could promote IA
223 formation in combination with other deleterious genetic or environmental factors such as high
224 blood pressure, which would act either directly by mechanical effects on the vessel walls or
225 indirectly by triggering inflammation (23).

226 CTSSO is one of the 11 cathepsins encoded in the human genome which constitute an
227 important group of proteases that regulate numerous processes (18). Cathepsins are highly
228 expressed in intracellular acidic compartments such as endosomes and lysosomes. Loss of
229 function mutations in their encoding genes cause very different syndromes in terms of clinical
230 symptoms and disease progression, corresponding to either typical lysosomal storage
231 diseases, or resulting from defective cleavage of specific protein substrates (24). Cathepsins

232 are also found in the cytoplasm, cell nucleus, cell membrane and the extracellular space (25,
233 26). Extracellular cathepsins mediate ECM protein degradation (collagen, elastin, fibronectin,
234 laminin) and the release of ECM-bound factors, but also shed various membrane proteins
235 including receptors, growth factors, cytokines, and adhesion proteins thereby influencing
236 important cellular processes such as proliferation and differentiation, motility, cell-cell
237 interaction, adhesion, inflammatory and immune responses. Indeed, extracellular cathepsins
238 are majorly upregulated in pathological states and are implicated in a wide range of disorders
239 including vascular remodeling and atherosclerotic diseases (27, 28). The cathepsins B, K and
240 S have been found to be upregulated in the wall of IA (29). Here we observed an increase in
241 CTSO expression, in particular in ECM, in ruptured human IA compared to unruptured IA. At
242 cell level, CTSO is expressed in endothelial cells, and more strongly in VSMC. CTSO was
243 found both in and around VSMC, and its extracellular release is stimulated by cell stretching,
244 suggesting that its role as an extracellular protease in the arterial wall could be potentiated by
245 high blood pressure and participated to the adaptive arterial remodeling induced by
246 hypertension. The increase in CTSO expression observed in ruptured IA domes could thus
247 result from the greater aneurysmal wall stretch induced by blood pressure in ruptured *versus*
248 unruptured IA (30).

249 CTSO is defined as a ubiquitous protein but neither its peptidase activity nor its
250 function had been characterized yet. Although we have not analyzed the enzymatic activity of
251 CTSO *in vitro* to directly demonstrate its ability to degrade FN, we provide a strong body of
252 experimental evidence to support this hypothesis. Cell adhesion and FAK activation are
253 potentiated by depletion of CTSO, both rapidly and late after VSMC seeding on exogenous
254 FN coating, while only delayed stimulation of FAK activation was observed in CTSO-
255 depleted VSMC seeded on plastic. These observations are consistent with a degradation of
256 pericellular FN by CTSO, which instantaneously impaired cell-FN coating interaction in

257 VSMC producing extracellular CTSO. When VSCM are seeded on plastic, the effect of
258 CTSO depletion is only visible at late time points, after the time necessary for the cells to self-
259 produce FN with which they establish adhesions. This hypothesis is in agreement with the
260 increase in the amount of FN in CTSO deficient VSMC and is further supported by the strong
261 immunofluorescence labeling of exogenous FN close to CTSO-depleted VSMC compared to
262 its low intensity in CTSO-expressing cells. All these observations suggest that extracellular
263 CTSO secreted by VSMC degrades FN. This was corroborated by the results obtained by the
264 expression of the two mutated proteins p.Val316Ile-CTSO and p.Ala43Val-CTSO which,
265 being weakly secreted, induce an increase in the amount of FN as does the depletion of
266 CTSO.

267 It is well established that adhesive properties to ECM drives VSMC stiffness (31), and
268 the level of activation of FAK signaling is related to VSMC stiffness (32). In particular,
269 VSMC focal adhesions to FN correlate with VSMC stiffness (33). The strong stiffening of
270 VSMC that we observed after CTSO depletion is therefore consistent with an increase in the
271 ability of VSMC to form adhesions to FN due to the reduced degradation of FN in CTSO-
272 depleted VSMC.

273 ECM composition and organization impact the physical interactions with VSMC, which
274 play a major role in regulating their functions, including migration and differentiation. We
275 observed that knocking-down CTSO reduced VSMC migration on FN. This result further
276 supports a role of CTSO in promoting FN degradation, although additional mechanisms could
277 also be involved such as degradation of other extracellular proteins or lysosomal degradation
278 of FN-bound integrins known to be required for migration.(34) Regarding VSMC
279 differentiation, CSTO depletion leads to increased expression of contractile phenotype marker
280 genes such as *Acta2*. Interestingly, deletion or inhibition of cathepsin B, characterized as a
281 FN-degrading protease (35) that is also up-regulated by cell stretching, also increases ACTA2

282 expression through an underlying mechanism that is still unknown (36). Increased ACTA2
283 expression has been shown to contribute to VSMC stiffening (37), suggesting that up-
284 regulation of *Acta2* and possibly of the other contractile markers, could participate to the
285 increase in VSMC stiffness induced by CTSO depletion. Although contractile markers were
286 upregulated, collagen gel contraction produced by KD-VSMC was reduced compared to
287 Cont-VSMC. Whether this effect was related to the stiffness of VSMC induced by CTSO
288 deletion could not be determined. Nevertheless, this possibility is supported by previous
289 results obtained on VSMC from aged animals showing a similar association between
290 increased stiffness (31) and reduced collagen gel contraction (33, 38).

291 Besides their contractile activity, VSMC produce ECM that allows adaptation to
292 mechanical forces that act on the vessel wall while maintaining adequate wall pressure (39, 40).
293 Thus, the composition, organization and resulting interactions of ECM with VSMC are adjusted
294 to the mechanical demands of the vessel wall through multiple and coordinated mechanisms.
295 Among them, the fine-tuning of extracellular protease expression and activity plays a major
296 role in ECM matrix reshaping (27). Our present study proposes that CTSO, whose secretion is
297 regulated by cell stretch, could be a new member of these ECM proteases involved in arterial
298 wall adaptation to mechanical stress. Indeed, we have identified CTSO as a potential new player
299 in arterial remodeling, regulating FN deposition and VSMC function. This role of CTSO is
300 consistent with an increased susceptibility to IA associated with non-secreted c.128C>T *CTSO*
301 and c.946G>A *CTSO* variants. We suggest that, by promoting increased FN deposition, VSMC-
302 FN adhesion and VSMC stiffening, the p.Val316Ile-CTSO and p.Ala43Val-CTSO mutants
303 affect the mechanical properties of the vessel wall and compromise the proper adaptation of the
304 arterial wall to local hemodynamics, thereby favoring IA formation. It is noteworthy that similar
305 features, namely faster adhesion to FN,(41) up-regulation of contractile marker expression and

306 increased stiffness, have been described in Marfan syndrome VSMC,(42) a well-known genetic
307 condition that predisposes to IA (43).

308

309 **Methods**

310 *Sex as a biological variable.* For experiments in SHR and SHRSP, only males have been used
311 as males showed higher blood pressure and greater incidence of stroke than females (44). For
312 analysis in humans, both males and females have been included.

313

314 *Clinical recruitment.* Familial cases of IA are defined as at least two first-degree relatives
315 both diagnosed with typical IA (defined as a saccular arterial dilatation of any size occurring
316 at a bifurcation of the intracranial vasculature), without any age limitation. Index case subjects
317 and their relatives were recruited according to a recruitment process previously described
318 (45). Briefly, neuroradiological phenotyping was performed in each recruiting center by
319 interventional neuroradiologists, neurologists, and neurosurgeons in order to recruit only case
320 subjects with typical saccular bifurcation IA. Mycotic, fusiform-shaped, or dissecting IAs
321 were systematically excluded, as well as IA in relation with an arteriovenous malformation
322 and IA resulting from syndromic disorders such as Marfan disease or vascular forms of Ehlers
323 Danlos. For all included patients we recorded the date of birth, if IA, the cases of rupture, the
324 number of IA, the IA larger diameter in mm, the IA locations according to the four following
325 groups internal carotid artery (ICA), posterior cerebral circulation (PCA), middle cerebral
326 artery (MCA) or anterior cerebral artery (ACA), the smoking habits, the history of high blood
327 pressure and ischemic stroke, the level of alcohol intake per week, the history of diabetes or
328 dyslipidemia, obesity (BMI >30), treatment by statin, antiplatelet, oral anticoagulant and anti-
329 inflammatory drugs.

330

331 *Whole Exome Sequencing (WES)*. Genomic DNA was extracted from peripheral blood
332 lymphocytes using the NucleoSpin Blood kit XL (Macherey Nagel). Whole-exome fragments
333 were captured with the SureSelect Human All Exon V4 kit (Agilent technology), according to
334 manufacturer protocol. Alignment on reference genome (Broad Institute human_g1k_v37) was
335 performed using Burrow-Wheeler aligner (Bwa mem v0.7.10).(46) Picard v1.119 was used to
336 flag duplicates and recalibration was achieved through GATK v3.2.2 (broadinstitute, 2023)
337 (47). Variants were called with GATK HaplotypeCaller on all exons hg9 exons (NCBI RefSeq),
338 annotated with SnpEff and vcfGnomad (jvarkit) using gnomad v2.1.(48) Quality filters detailed
339 in the Table S1 were applied. Only variants annotated as non-synonymous or affecting splicing,
340 and reported with a minor allelic frequency (MAF) below 0.1% in the non-Finnish European
341 (NFE) gnomAD population, were subsequently considered.

342
343 ***IBD analysis.*** Haplotype sharing between affected relatives were identified through IBD
344 analysis based on SNP genotyping data. Fluorescence intensities were obtained from
345 Precision Medicine Research Array (PMRA - Affymetrix) and quantified by Affymetrix
346 GeneTitan Multi-Channel Instrument. Genotypes of affected relatives II.2, II.9, III.2, III.4 and
347 III.7 were merged with PREGO control population (49) and SNPs with MAF<10%, call rate <
348 95% or $p < 1.10^{-5}$ when testing for Hardy-Weinberg equilibrium were excluded. IBD regions
349 were then identified using IBDLD v3.34 with noLD method (50). Familial segregation
350 analysis by capillary sequencing was performed on an Applied Biosystems 3730 DNA
351 Analyzer, using standard procedures. Sequence analyses were performed with SeqScape
352 v.2.5.

353
354 ***Human Saccular IA Samples.*** Saccular IA samples are from the Aneux Biobank (51). All
355 samples were obtained during microsurgery by resection of the IA dome (i.e., the bulging

356 region of the IA) after clipping of the neck performed at the Division of Neurosurgery of the
357 Geneva University Hospitals, Switzerland. IAs were stored as previously described (51), fixed
358 in formol, embedded in paraffin, sectioned at 5 μ m and conserved at 4°C.

359
360 *Immunohistochemistry.* Labeling of 4- μ m-thick sections was performed following heat-
361 induced epitope retrieval in citrate buffer (10 mM, pH 6.0). Sections of unruptured (n=10) and
362 ruptured (n=10) IA were immunolabeled with the Prestige Antibodies® antibody recognizing
363 CTSO (HPA002041, Sigma-Aldrich). Negative controls were performed without CTSO
364 antibody. Hematoxylin and eosin were used as counterstaining. Image acquisition of
365 immunohistochemical staining of CTSO was done with a whole-slide scanner NanoZoomer
366 (Hamamatsu). Total tissue area and positive staining area were quantified using Image-Pro
367 Plus (Media Cybernetics), and the positive CTSO staining was expressed relative to total
368 sample area.

369
370 *Animal model.* Cerebral arteries from 3 months-old Wistar-Kyoto (WKY), spontaneously
371 hypertensive (SHR) and stroke-prone SHR (SPSHR) male rats (300 g) were collected and
372 snap-frozen in liquid nitrogen for RNA extraction. WKY were used for VSMC isolation.

373
374 *Cell culture.* Primary VSMC were isolated from the aorta of 4-week-old WYK rats. Rats were
375 sacrificed according to institutional animal handling ethics. The aorta was harvested, cleaned,
376 endothelium-denuded, cut into small pieces and digested by collagenase II (1 mg/mL; 2 h at
377 37°C under agitation; Worthington Bio-chemical). After inactivation of collagenase with
378 serum, the tissue was spun down and plated in a 6-well plate in Dulbecco modified Eagle
379 medium (DMEM, Gibco; Invitrogen) containing 10% foetal bovine serum (FBS), 4.5 g/L
380 glucose, 100 units/mL penicillin and 100 μ g/mL streptomycin at 37°C-5% CO₂. All

381 experiments were performed at passages 2 and 3. For cell stretching, cyclic uniaxial strain
382 was applied at 1 Hz and 10% or 20% strain for 24 hours (MechanoCulture FX, CellScale).
383 HUVEC (passage 2 to 6; PromoCell) were routinely cultured in EBM media supplemented
384 with the provided growth factors kit (Promocell). For flow experiments HUVEC were
385 cultured on 0.2% gelatin-coated 0.4 ibidi slides (IBIDI) and unidirectional laminar shear
386 stress was applied using the pumping system and control unit form IBIDI. Local shear stress
387 was calculated using Poiseuille's law and averaged to 3 dyn/cm² (pathological low shear
388 stress: LSS) 16 dyn/cm² (physiological shear stress: PSS) or 36 dyn/cm² (pathological high
389 shear stress: HSS). NIH3T3 cells were cultured in DMEM containing 1 g/L glucose, 10%
390 FBS, 100 units/mL penicillin and 100 µg/mL streptomycin at 37°C-5% CO₂.

391
392 *RT-qPCR.* Total RNA was purified from cells using RNA plus kit (Macherey Nagel) or tissue
393 using TRIzol reagent (MAN0001271, Ambion, Thermo Fisher Scientific) and RNA XS Plus
394 kit (Macherey Nagel) according to the manufacturer instructions. RNA (500 ng) was reverse-
395 transcribed with M-MLV enzyme (28025021, Thermo Fisher Scientific). Real-time qPCR
396 was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems) using SYBR
397 Green Master Mix (4367659, Applied Biosystems) and primers listed in Table S4. Each
398 sample was analyzed in triplicate. GAPDH was used as the reference gene and results are
399 expressed according to the 2^{-ΔΔCt} method.

400
401 *Immunoblotting.* Supernatant from VSMC or NIH3T3 were taken off and concentrated with
402 Amicon Ultra-0.5 Centrifugal Filter Unit (UFC5010, Millipore). Cells were lysed on ice in
403 buffer supplemented with protease and phosphatase inhibitor cocktails (Sigma Aldrich) and
404 sodium orthovanadate. Equal amount of proteins of each sample was separated by SDS-
405 PAGE, transferred to nitrocellulose membranes, and incubated with specific antibodies:

406 CTSO (for rat form: ab200735, Abcam, for human form: HPA002041, Sigma-Aldrich),
407 cleaved caspase 3 (9664, Cell Signalling Technology), P-FAK (8556, Cell Signalling
408 Technology), FAK (3285, Cell Signalling Technology), Fibronectin (15613-1-AP,
409 Proteintech), type I collagen (14695-1-AP, Proteintech). Equal loading was checked by
410 reprobing of the membrane with an anti-tubulin antibody (T9026, Sigma). Immune complexes
411 were detected with appropriate secondary antibodies and enhanced chemiluminescence
412 reagent (Clarity ECL BioRad). Protein band intensities were quantified using ImageJ
413 Software (NIH software, Bethesda, Md).

414
415 *Ctso* silencing. VSMC were transfected using Lipofectamine RNAiMAX reagent (Invitrogen)
416 according to the manufacturer instructions with a pool of siRNAs targeting rat *Ctso* (ON-
417 TARGETplus siRNA-SMARTpool (Cat# L-110260-00-0005; Horizon Discovery,) and a non-
418 targeting control pool (Pool #1, D-001810-10-05, Horizon Discovery) to generate KD-SMC
419 and Cont-SMC, respectively. The efficiency of *Ctso* mRNA depletion was assessed 72 h post-
420 transfection by RT-qPCR.

421
422 *Viability/Proliferation assay.* VSMC viability/proliferation was quantified by MTT (3-[4,5
423 Dimethylthiazol-2-yl]-2,5-diphenyltetrazodium) colorimetric assay according to the
424 manufacturer instructions (M5655; Sigma-Aldrich). Briefly, VSMC were seeded onto 96-well
425 plates in triplicate for each condition, cultured for 24 h, after which they were serum-starved
426 for 24 h. VSMC were then incubated in DMEM without or with 10% FBS for 24h. The
427 number of viable cells was then determined by incubation in 1 mg/mL MTT for 4 h à 37 °C.
428 The medium was then removed and acidified isopropanol was added to solubilize the MTT
429 reduction product formazan. MTT reduction by viable cells was then quantified by
430 measurement of the absorbance at 590 nm.

431

432 *Apoptosis assay.* VSMC apoptosis was determined after incubation in 1 $\mu\text{mol/L}$ staurosporine
433 (S5921, Sigma-Aldrich) in serum-free medium for 8 h. Apoptosis was quantified by the
434 measurement of cleaved caspase 3 by western blot and by TUNEL assay. VSMC were fixed
435 with 4% paraformaldehyde and permeabilized. Fragmented DNA was stained with TUNEL
436 Assay Kit - BrdU-Red (ab66110, Abcam) according to manufacturer instructions, and DAPI
437 was used to label all nuclei. Coverslips were mounted on slides with Prolong gold antifade
438 reagent and observed with a fluorescent microscope. Apoptotic cell number was quantified as
439 the percentage of TUNEL-positive cells.

440

441 *Transwell migration assay.* Boyden chamber assay was performed as previously described
442 (52). VSMC, transfected with siRNA 48 h before, were trypsinized and washed in serum-free
443 DMEM before plating into transwells (0.47cm^2 of culture area, 8 μm pore size; Nunc™).
444 DMEM containing 10% FCS was placed in the lower chamber and VSMC were allowed to
445 migrate for 10 h at 37 °C. After incubation, the filter was removed and VSMC on the upper
446 side of the filter were scraped off. VSMC that had migrated to the lower side of the filter were
447 fixed with 4% paraformaldehyde and stained with Coomassie blue 0.1% for observation under
448 a microscope in brightfield mode. Migration to the lower chamber of the transwell was
449 quantified by the area covered by cells measured using ImageJ Software and expressed
450 expressed relative to Cont-SMC set as 1.

451

452 *Cell adhesion assay using impedance technology.* VSMC (10000/well) were seeded in a 96
453 well plate microtiter xCELLigence assay plate coated with 2 $\mu\text{g/ml}$ fibronectin (E-Plate,
454 ACEA Biosciences Inc.) and placed on the Real-time xCELLigence Cell Analyzer (Roche
455 Applied Science) platform at 37°C. The cell index value, which are proportionate to the area

456 covered by the cells was measured every 5 min for a period of 8 h. Adhesion speed was
457 defined as the slope of the cell index change over time.

458

459 *Collagen gel contraction assay.* VSMC were mixed with collagen gel working solution
460 (CBA-201, Cell Biolabs). The cell-collagen mixture was added into a 24-well plate and
461 incubated at 37°C for 1 h to allow collagen polymerization. Serum-free DMEM was added to
462 the top of the collagen gel lattice. After 24 h, cells were treated or not with U46619 (10⁻⁶
463 mol/L) and the myosin inhibitor BDM (from CBA-201 kit), and the collagen gels were
464 released by a sterile spatula. Changes in the collagen gel area were measured at 48 h. The
465 percentage of contraction corresponded to [(area in BDM condition-area in the control or
466 U46619 condition)/ area in BDM condition × 100].

467

468 *Immunofluorescence.* VSMC were seeded onto culture plates pre-coated with human FN
469 (F2006, Sigma-Aldrich, 20 µg/ml). After 24-hour of culture, cells were fixed with 4%
470 paraformaldehyde for 15 min, rinsed twice with PBS, then permeabilized and blocked for 1 h
471 with carbonate-bicarbonate buffer containing 1% FBS, 3% BSA, 0.5% Triton X-100, 0.01%
472 deoxycholate, 0.02% sodium azide. FN was stained with anti-human FN antibody (F3648,
473 Sigma-Aldrich; 1/500 overnight), revealed by a secondary Alexa647-conjugated donkey anti-
474 rabbit antibody (LifeTech; 1/1000, 2 h). Actin staining was performed at room temperature
475 using phalloidin Alexa Fluor™ 488 (A12379, Fisher Scientific; 1/400, 45 min). Images were
476 taken using Nikon A1 confocal microscope (Nikon France, Champigny sur Marne) equipped
477 with a x60 Plan-Apochromat objective with a numerical Aperture of 1.4. FN fluorescence was
478 quantified using FIJI. Briefly, for each cell a mask corresponding to the cell area was
479 generated and applied on the FN staining image. FN fluorescence intensity in this area was
480 extracted for each cell.

481

482 *Atomic force microscopy (AFM) experiments.* AFM experiments have been performed in Cont-
483 and KD-SMC grown on plastic and allowed to produce their own ECM for 5 days. ECM
484 analysis has been performed after decellularization as previously described (53). All
485 experiments were then performed in Physiological Saline Solutions (PSS) buffered with 20 mM
486 HEPES at 37°C using a NanoWizard® atomic force microscope (JPK Instruments, Germany)
487 equipped with a temperature controller and inverted optical microscope. Indentation
488 experiments were carried out with cantilevers (SQube) having a colloidal glass sphere of 5 µm
489 in diameter. Their spring constant was calibrated using the thermal noise method implemented
490 in the AFM setting (JPK software), with values comprised between 0.12 and 0.15 N.m⁻¹. Prior
491 to indentation measurements, the cantilever sensitivity was systematically measured from the
492 slope of force-distance curves performed on glass. The optical microscope was first used to
493 position the AFM tip on ECM or on the cytoplasmic region of the selected cell and several
494 approach-retract force-distance curves were performed to determine the force to be applied
495 corresponding to an indentation depth of ~500 nm (a good compromise avoiding the long-range
496 interactions and in the validity domain of the Hertz contact mechanics model). Then, force-
497 distance curves were recorded on cells at a low constant speed of 1 µm/s to neglect the
498 hydrodynamic drag forces exerted on the cantilever by the liquid medium (54). These curves
499 were then converted into force-indentation curves, and the approach part was fitted by the Hertz
500 model to determine the apparent elastic modulus of cells (55).

501

502 *Mutagenesis.* CTSO-TurboGFPpPlasmid was purchased from Origene (RG208268).
503 c.128C>T *CTSO* and c.946G>A *CTSO* mutagenesis was performed using Q5® Site-Directed
504 Mutagenesis Kit Protocol (E0554, NEB) and designed primers: A43V-Fw: 5'-GAA
505 GCCGCCGTCTTCCGGGAAAGTC-3'; A43V-Rv: 5'-ACG CTCGCGGCTCCGCGG-3';

506 V316I-Fw: 5'-GTTTGTGGTATTGCAGATTCCATTTCTTCTATATTTGTGACGC-3';
507 V316I-Rv: 5'-GCGTCACAAATATAGAAGAAATGGAATCTGCAATACCACAAAC-3'.
508 Mutations were confirmed by standard sequencing methods using T7 standard primer and
509 designed primer (5'-AAGCCCCTGGAAGACCTAAG-3').
510
511 *Generation of lentiviral constructs.* From LT3GEPiR plasmid (#111177, Addgene), was
512 modified to remove miR30 backbone by amplifying and cloning eGFP between XhoI and
513 EcoRI restriction sites using the following primers: Fw 5'-
514 CGGCCGCTCGAGATGGTGAGCAAGGGCGAGGAG-3' and Rv 5'
515 GATCTGAATTCTTACTTGTACAGCTCGTCCATGC-3'. The resulting plasmid was used
516 to clone WT and mutant CTSO in BamHI and XhoI,
517
518 *Lentivirus production, transduction and induction of WT-CTSO and CTSO variants.*
519 Lentiviral vector for expressing WT-CTSO, p.Ala43Val-CTSO and p.Val316Ile-CTSO was
520 transfected into HEK293T cells along with packaging vectors psPAX2 and pVSVG2
521 (provided by Dr. Utz Fischer's lab) using polyethylenimine (#764965, Sigma-Aldrich)
522 transfection agent. After overnight incubation, the medium was replaced with fresh medium
523 (DMEM+10% serum). Forty-eight hours and 72 h after transfection, viral supernatant was
524 collected, filtered through 0.22 µm filter and used to infect NIH3T3 in the presence of
525 polybrene (8 µg/mL, H9268; Sigma-Aldrich). After 48 to 72 h of infection, transduced
526 NIH3T3 cells were selected with puromycin (2 µg/mL, P8833, Sigma-Aldrich) for 48 h and
527 maintained in the presence of puromycin (2 µg/mL). The induction of WT- or mutated CTSO
528 was performed at least 2 days before the experiment by supplementing the medium with
529 doxycycline (1 µg/mL, #D9891, Sigma Aldrich), which was maintained until the completion
530 of the experimental procedure.

531

532 *Statistical analysis.* Data are expressed as the mean \pm SEM of sample size n. All values use
533 biological replicates and are indicated by group size n in figure legends or within graphs. For
534 *in vivo* data, each n value corresponds to a single animal. For *in vitro* data, each n value
535 corresponds to an independent experiment. Investigators were blinded for some measurements
536 made (i.e., immunofluorescence, immunohistology, area measurement). Comparisons
537 between two groups were performed by unpaired, two tailed nonparametric Mann-Whitney *U*
538 test, and one-way ANOVA with relevant *post hoc* tests was used for multiple-group
539 comparisons using GraphPad Prism 6.0 software (GraphPad Software). $P < 0.05$ was
540 considered statistically significant.

541

542 *Study approval.* All animal care and use procedures of the present study were performed in
543 accordance with the European Union Directive 2010/63/EU about the protection of animals
544 used for scientific purposes and were authorized by the Ethics Committee on Animal
545 Experimentation from the Région Pays de la Loire (approval number D44278). For genetic
546 analysis, index case subjects with IA and their relatives were recruited following the French
547 ethical guidelines for genetic research and under approval from the French Ministry of
548 Research and the local ethical committee (no. DC-2011-1399; Clinical Trial NCT02712892).
549 Informed written consent was obtained from each individual agreeing to participate in the
550 genetic study, to whom MRI screening and blood sampling were proposed. AneuX biobank
551 was approved by the Geneva State Ethics Commission for Research involving humans
552 (Geneva CCER 2022-00426). All patients approved for the use of their data and biological
553 samples in the field of cerebrovascular research. Research was conducted in accordance with
554 the Declaration of Helsinki.

555

556 *Data availability.* All data needed to support the conclusions of this study are present in the
557 paper and/or the Supplementary Materials or are available via the corresponding authors upon
558 reasonable request. Values for all data points are available in the Supporting Data Values file.

559

560 REFERENCES

- 561 1. Vlak MH, Algra A, Brandenburg R, and Rinkel GJ. Prevalence of unruptured intracranial
562 aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic
563 review and meta-analysis. *Lancet Neurol.* 2011;10(7):626-36.
- 564 2. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, and Rinkel GJ. Changes in case fatality
565 of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a
566 meta-analysis. *Lancet Neurol.* 2009;8(7):635-42.
- 567 3. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G, et al. European Stroke
568 Organization guidelines for the management of intracranial aneurysms and subarachnoid
569 haemorrhage. *Cerebrovasc Dis.* 2013;35(2):93-112.
- 570 4. Vlak MH, Rinkel GJ, Greebe P, and Algra A. Risk of rupture of an intracranial aneurysm based
571 on patient characteristics: a case-control study. *Stroke.* 2013;44(5):1256-9.
- 572 5. Bourcier R, Redon R, and Desal H. Genetic investigations on intracranial aneurysm: update
573 and perspectives. *J Neuroradiol.* 2015;42(2):67-71.
- 574 6. Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, et al. Subarachnoid
575 hemorrhage: a preventable disease with a heritable component. *Stroke.* 2002;33(5):1321-6.
- 576 7. Bakker MK, van der Spek RAA, van Rheenen W, Morel S, Bourcier R, Hostettler IC, et al.
577 Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic
578 overlap with clinical risk factors. *Nat Genet.* 2020;52(12):1303-13.
- 579 8. Bilguvar K, Yasuno K, Niemela M, Ruigrok YM, von Und Zu Fraunberg M, van Duijn CM, et al.
580 Susceptibility loci for intracranial aneurysm in European and Japanese populations. *Nat*
581 *Genet.* 2008;40(12):1472-7.
- 582 9. Yasuno K, Bakircioglu M, Low SK, Bilguvar K, Gaal E, Ruigrok YM, et al. Common variant near
583 the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk.
584 *Proc Natl Acad Sci U S A.* 2011;108(49):19707-12.
- 585 10. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Kirschek B, Auburger G, et al. Genome-wide
586 association study of intracranial aneurysm identifies three new risk loci. *Nat Genet.*
587 2010;42(5):420-5.
- 588 11. Zhou S, Ambalavanan A, Rochefort D, Xie P, Bourassa CV, Hince P, et al. RNF213 Is Associated
589 with Intracranial Aneurysms in the French-Canadian Population. *Am J Hum Genet.*
590 2016;99(5):1072-85.
- 591 12. Santiago-Sim T, Fang X, Hennessy ML, Nalbach SV, DePalma SR, Lee MS, et al. THSD1
592 (Thrombospondin Type 1 Domain Containing Protein 1) Mutation in the Pathogenesis of
593 Intracranial Aneurysm and Subarachnoid Hemorrhage. *Stroke.* 2016;47(12):3005-13.
- 594 13. Wu Y, Li Z, Shi Y, Chen L, Tan H, Wang Z, et al. Exome Sequencing Identifies LOXL2 Mutation
595 as a Cause of Familial Intracranial Aneurysm. *World Neurosurg.* 2018;109:e812-e8.
- 596 14. Lorenzo-Betancor O, Blackburn PR, Edwards E, Vazquez-do-Campo R, Klee EW, Labbe C, et al.
597 PCNT point mutations and familial intracranial aneurysms. *Neurology.* 2018;91(23):e2170-
598 e81.
- 599 15. Yang X, Li J, Fang Y, Zhang Z, Jin D, Chen X, et al. Rho Guanine Nucleotide Exchange Factor
600 ARHGEF17 Is a Risk Gene for Intracranial Aneurysms. *Circ Genom Precis Med.*
601 2018;11(7):e002099.

- 602 16. Bourcier R, Le Scouarnec S, Bonnaud S, Karakachoff M, Bourcereau E, Heurtebise-Chretien S,
603 et al. Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial
604 Aneurysm. *Am J Hum Genet.* 2018;102(1):133-41.
- 605 17. Barak T, Ristori E, Ercan-Sencicek AG, Miyagishima DF, Nelson-Williams C, Dong W, et al.
606 PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans.
607 *Nat Med.* 2021;27(12):2165-75.
- 608 18. Reiser J, Adair B, and Reinheckel T. Specialized roles for cysteine cathepsins in health and
609 disease. *J Clin Invest.* 2010;120(10):3421-31.
- 610 19. Hedin U, Bottger BA, Forsberg E, Johansson S, and Thyberg J. Diverse effects of fibronectin
611 and laminin on phenotypic properties of cultured arterial smooth muscle cells. *J Cell Biol.*
612 1988;107(1):307-19.
- 613 20. Yang P, Troncone L, Augur ZM, Kim SSJ, McNeil ME, and Yu PB. The role of bone
614 morphogenetic protein signaling in vascular calcification. *Bone.* 2020;141:115542.
- 615 21. Matsukawa H, Shinoda M, Fujii M, Uemura A, Takahashi O, and Niimi Y. Arterial stiffness as a
616 risk factor for cerebral aneurysm. *Acta Neurol Scand.* 2014;130(6):394-9.
- 617 22. Vlak MH, Rinkel GJ, Greebe P, and Algra A. Independent risk factors for intracranial
618 aneurysms and their joint effect: a case-control study. *Stroke.* 2013;44(4):984-7.
- 619 23. Hudson JS, Hoyne DS, and Hasan DM. Inflammation and human cerebral aneurysms: current
620 and future treatment prospects. *Future Neurol.* 2013;8(6).
- 621 24. Ketscher A, Ketterer S, Dollwet-Mack S, Reif U, and Reinheckel T. Neuroectoderm-specific
622 deletion of cathepsin D in mice models human inherited neuronal ceroid lipofuscinosis type
623 10. *Biochimie.* 2016;122:219-26.
- 624 25. Vidak E, Javorsek U, Vizovisek M, and Turk B. Cysteine Cathepsins and their Extracellular
625 Roles: Shaping the Microenvironment. *Cells.* 2019;8(3).
- 626 26. Yadati T, Houben T, Bitorina A, and Shiri-Sverdlov R. The Ins and Outs of Cathepsins:
627 Physiological Function and Role in Disease Management. *Cells.* 2020;9(7).
- 628 27. Liu CL, Guo J, Zhang X, Sukhova GK, Libby P, and Shi GP. Cysteine protease cathepsins in
629 cardiovascular disease: from basic research to clinical trials. *Nat Rev Cardiol.* 2018;15(6):351-
630 70.
- 631 28. Wu H, Du Q, Dai Q, Ge J, and Cheng X. Cysteine Protease Cathepsins in Atherosclerotic
632 Cardiovascular Diseases. *J Atheroscler Thromb.* 2018;25(2):111-23.
- 633 29. Aoki T, Kataoka H, Ishibashi R, Nozaki K, and Hashimoto N. Cathepsin B, K, and S are
634 expressed in cerebral aneurysms and promote the progression of cerebral aneurysms.
635 *Stroke.* 2008;39(9):2603-10.
- 636 30. Oliveira IL, Cardiff P, Baccin CE, and Gasche JL. A numerical investigation of the mechanics of
637 intracranial aneurysms walls: Assessing the influence of tissue hyperelastic laws and
638 heterogeneous properties on the stress and stretch fields. *J Mech Behav Biomed.*
639 2022;136:105498.
- 640 31. Lacolley P, Regnault V, and Avolio AP. Smooth muscle cell and arterial aging: basic and clinical
641 aspects. *Cardiovasc Res.* 2018;114(4):513-28.
- 642 32. Saphirstein RJ, Gao YZ, Jensen MH, Gallant CM, Vetterkind S, Moore JR, et al. The focal
643 adhesion: a regulated component of aortic stiffness. *PLoS One.* 2013;8(4):e62461.
- 644 33. Sehgel NL, Sun Z, Hong Z, Hunter WC, Hill MA, Vatner DE, et al. Augmented vascular smooth
645 muscle cell stiffness and adhesion when hypertension is superimposed on aging.
646 *Hypertension.* 2015;65(2):370-7.
- 647 34. Lobert VH, Brech A, Pedersen NM, Wesche J, Oppelt A, Malerod L, et al. Ubiquitination of
648 alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of
649 fibronectin-integrin complexes. *Dev Cell.* 2010;19(1):148-59.
- 650 35. Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF. Degradation of extracellular-matrix
651 proteins by human cathepsin B from normal and tumour tissues. *Biochem J.* 1992;282 (Pt
652 1)(Pt 1):273-8.

- 653 36. Nettesheim A, Shim MS, Dixon A, Raychaudhuri U, Gong H, and Liton PB. Cathepsin B
654 Localizes in the Caveolae and Participates in the Proteolytic Cascade in Trabecular Meshwork
655 Cells. Potential New Drug Target for the Treatment of Glaucoma. *J Clin Med*. 2020;10(1).
656 37. Qiu H, Zhu Y, Sun Z, Trzeciakowski JP, Gansner M, Depre C, et al. Short communication:
657 vascular smooth muscle cell stiffness as a mechanism for increased aortic stiffness with
658 aging. *Circ Res*. 2010;107(5):615-9.
659 38. Wheeler JB, Mukherjee R, Stroud RE, Jones JA, and Ikonomidis JS. Relation of murine thoracic
660 aortic structural and cellular changes with aging to passive and active mechanical properties.
661 *J Am Heart Assoc*. 2015;4(3):e001744.
662 39. Humphrey JD, and Schwartz MA. Vascular Mechanobiology: Homeostasis, Adaptation, and
663 Disease. *Annu Rev Biomed Eng*. 2021;23:1-27.
664 40. Lin PK, and Davis GE. Extracellular Matrix Remodeling in Vascular Disease: Defining Its
665 Regulators and Pathological Influence. *Arterioscler Thromb Vasc Biol*. 2023;43(9):1599-616.
666 41. Nolasco P, Fernandes CG, Ribeiro-Silva JC, Oliveira PVS, Sacrini M, de Brito IV, et al. Impaired
667 vascular smooth muscle cell force-generating capacity and phenotypic deregulation in
668 Marfan Syndrome mice. *Biochim Biophys Acta Mol Basis Dis*. 2020;1866(1):165587.
669 42. Crosas-Molist E, Meirelles T, Lopez-Luque J, Serra-Peinado C, Selva J, Caja L, et al. Vascular
670 smooth muscle cell phenotypic changes in patients with Marfan syndrome. *Arterioscler*
671 *Thromb Vasc Biol*. 2015;35(4):960-72.
672 43. Kim JH, Kim JW, Song SW, Ahn SJ, Park M, Park SK, et al. Intracranial Aneurysms Are
673 Associated With Marfan Syndrome: Single Cohort Retrospective Study in 118 Patients Using
674 Brain Imaging. *Stroke*. 2021;52(1):331-4.
675 44. Okamoto K, Yamori Y, and Nagaoka A. Establishment of the stroke-prone spontaneously
676 hypertensive rat (SHR). *Circ Res*. 1974;34/35(Suppl 1):143-53.
677 45. Bourcier R, Chatel S, Bourcereau E, Jouan S, Marec HL, Daumas-Duport B, et al.
678 Understanding the Pathophysiology of Intracranial Aneurysm: The ICAN Project.
679 *Neurosurgery*. 2017;80(4):621-6.
680 46. Li H, and Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.
681 *Bioinformatics*. 2010;26(5):589-95.
682 47. Poplin R, Ruano-Rubio V, DePristo MA, Fennell TJ, Carneiro MO, Van der Auwera GA, et al.
683 Scaling accurate genetic variant discovery to tens of thousands of samples. *BioRxiv*.
684 2017:201178.
685 48. Karczewski KJ, Solomonson M, Chao KR, Goodrich JK, Tiao G, Lu W, et al. Systematic single-
686 variant and gene-based association testing of thousands of phenotypes in 394,841 UK
687 Biobank exomes. *Cell Genom*. 2022;2(9):100168.
688 49. Alves I, Giemza J, Blum M, Bernhardsson C, Chatel S, Karakachoff M, et al.: bioRxiv; 2022.
689 50. Han L, and Abney M. Identity by descent estimation with dense genome-wide genotype data.
690 *Genet Epidemiol*. 2011;35(6):557-67.
691 51. Morel S, Diagbouga MR, Dupuy N, Sutter E, Braunersreuther V, Pelli G, et al. Correlating
692 Clinical Risk Factors and Histological Features in Ruptured and Unruptured Human
693 Intracranial Aneurysms: The Swiss AneuX Study. *J Neuropathol Exp Neurol*. 2018;77(7):555-
694 66.
695 52. Gouëffic Y, Guilluy C, Guérin P, Patra P, Pacaud P, and Loirand G. Hyaluronan induces
696 vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac
697 activation. *Cardiovasc Res*. 2006;72(2):339-48.
698 53. Ozguldez HO, Cha J, Hong Y, Koh I, and Kim P. Nanoengineered, cell-derived extracellular
699 matrix influences ECM-related gene expression of mesenchymal stem cells. *Biomaterials*
700 *Research*. 2018;22(1):32.
701 54. Cuenot S, Gélébart P, Siquin C, Collic-Jouault S, and Zykwinska A. Mechanical relaxations of
702 hydrogels governed by their physical or chemical crosslinks. *J Mech Behav Biomed*. 2022;133.

703 55. Zykwinska A, Makshakova O, Gelebart P, Siquin C, Stephant N, Collic-Jouault S, et al.
704 Interactions between infernan and calcium: From the molecular level to the mechanical
705 properties of microgels. *Carbohydr Polym.* 2022;292:119629.

706

707 **ACKNOWLEDGEMENTS**

708 This work was supported by the French national research agency (ANR) (Programme
709 d'Investissements d'Avenir ANR-16-IDEX-0007 [NeXT Initiative], ANR-21-CE17-0006 [to
710 RBo], ANR-21-CE14-0016 [to A-CV], and ANR-15-CE17-0008-01 and ANR-23-CE14-0001
711 [to GL]), Fondation pour la Recherche Médicale (R22131NN - RAD22168NNA to GL), Institut
712 de France – Académie des Sciences (Lamonica Award to GL, supporting M-AM), the Inserm
713 and Regional Council of Pays de la Loire (to RB) and the local fund Genavie (to MF and RR).
714 Study benefited of the framework of the AneuX project supported by grants from SystemsX.ch,
715 and evaluated by the Swiss National Science Foundation (2014/261) exploiting the
716 infrastructure previously elaborated during the @neurIST project supported by the 6th
717 framework program of the European Commission (FP6-IST-2004-027703). We are grateful to
718 the genomics (GenoA), bioinformatics (BiRD) and microscopy core facilities (MicroPICell)
719 (SFR Bonamy, Nantes, France), members of Biogenouest and IBISA, for their expert services.
720 We also thank the *Institut Français de Bioinformatique* (IFB; ANR-11-INBS-0013) as well as
721 the animal house facility (UTE) of Nantes Université. We would like to thank the Genome
722 Aggregation Database (gnomAD) and the groups that provided exome and genome variant data
723 to this resource. A full list of contributing groups can be found at
724 <http://gnomad.broadinstitute.org/about>. We acknowledge the Center of Biological Resources
725 (CHU Nantes, Hôtel-Dieu, CBR, Nantes, France) as well as Martine Le Cunff and Marie-
726 France Le Cunff and the Clinical Investigation Center 1413 of Nantes for their assistance in
727 managing the ICAN and PREGO biobanks.

728

729 **AUTHOR CONTRIBUTIONS**

730 RB, GL and RR designed the research. SCh , EB, SJ, AC, CD, JO, HD, RB and ICAN Study
731 group were involved in the recruitment of IA patients. SM, BRK and PhB, and provided
732 human IA samples. Genetic data have been obtained and analyzed by RB, SBe, SBo, PL, FL,
733 J-FD, CD and RR. MF, M-AM, SPRB, MR, TQ, MB and A-CV performed CTSO function
734 and expression experiments and analyzed the results. SCu performed atomic force microscopy
735 experiments. MF. and RB shared the first-author position for their major contribution to the
736 study: M.F for functional analysis and R.B. for genetic analyses. GL and RR equally
737 contributed to the management of the project, analysis and interpretation of the data and the
738 writing of the manuscript. All authors discussed the results, red, commented and approved the
739 final manuscript.
740




741

742

743 **Figure 1. Angiography of two subjects from families with IA. (A)** Digital subtracted
744 angiography showing two IA carried by the index case II-9 of family A: one located on the
745 middle cerebral artery and already treated by coiling (white arrow), and one located on the
746 posterior communicating artery (black arrow). **(B)** Digital subtracted angiography showing
747 one ruptured ICA just before treatment, located on the anterior communicating artery (white
748 arrow).


749



750

751

752 **Figure 2. CTSO expression in arteries, smooth muscle and endothelial cells.** (A) *Ctso*
 753 mRNA expression analyzed by quantitative RT-PCR in cerebral arteries of normotensive
 754 (WKY), and hypertensive rats (SHR and SHRSP). (B) *Ctso* mRNA expression analyzed by
 755 quantitative RT-PCR in VSMC cultured in static condition and subjected to 10% and 20%
 756 cyclic stretch. (C) *CTSO* mRNA expression analyzed by quantitative RT-PCR in HUVEC
 757 under static condition and under flow generating low (LSS, 3 dyn/cm²), physiological (PSS,
 758 16 dyn/cm²) and very high (HSS, 36 dyn/cm²) shear stress. Means \pm SEM are shown. (D)
 759 CTSO expression in HUVEC under static condition and under flow (LSS, PSS and HSS) and
 760 representative Western blots. GAPDH was also blotted to check equal loading. (E)
 761 Representative western blots and quantification of CTSO protein expression assessed in cell
 762 lysate and culture medium of VSMC cultured in static condition and subjected to 10% and
 763 20% cyclic stretch. (Data are expressed as mean \pm SEM; ** p <0.01 and *** p <0.001; one-way
 764 ANOVA).




765

766

767 **Figure 3. Expression of CTSO in human IA domes.** (A and B) Representative whole
768 images of immunohistochemical staining of CTSO (in brown) (A) and quantification of CTSO
769 positive area (B) in human unruptured and ruptured IA domes. The black rectangles represent
770 the region shown at higher magnification in the bottom right-hand corner of each image.

771 (Results were expressed as mean \pm SEM; * $p < 0.05$; Mann-Whitney test).

772



773

774

775 **Figure 4 Consequence of CTSO depletion on VSMC proliferation, apoptosis, migration**

776 **and adhesion.** (A) Proliferation assessed by the measurement of MTT absorbance in the

777 absence and presence of 10% serum in VSMC transfected with siRNA targeting *Ctso* (KD-

778 SMC) and control siRNA (Cont-SMC). (B), Number of apoptic cells in KD-SMC and Cont-

779 SMC culture after stimulation with staurosporine (1 $\mu\text{mol/L}$, 8 h). Values represent the

780 percentage of TUNEL-positive cells relative to total cell population in each group. (C)

781 Typical Western blot of cleaved-caspase 3 in Cont- and KD-SMC and corresponding

782 quantification. CTSO and tubulin have been also blotted to check CTSO silencing and equal

783 loading. (D) Representative images of Cont- and KD-SMC which migrated to the underside


784 surface of transwell membranes and the corresponding quantification. (E) Representative

785 curve showing the cell index representing the adhesion of Cont- and KD-SMC over time and

786 quantification of the adhesion speed. (Results were expressed relative to Cont-SMC set as 1

787 (except in B). Data are presented as mean \pm SEM; * $p < 0.05$, ** $p < 0.01$; one-way ANOVA in

788 A; Mann-Whitney test in (B-E)).



789

790

791 **Figure 5. CTSO depletion in VSMC stimulates FAK phosphorylation and FN**

792 **expression.** (A and B) Representative Western blots showing the phosphorylation of FAK in

793 Cont- and KD-SMC 2 h and 24 h after seeding on FN matrix (A) or directly on plastic (B).

794 Graphs show densitometric analysis of phospho-FAK in blots, relative to FAK expression.

795 (C) Representative western blots showing the amount of FN and Col-I in Cont- and KD-SMC

796 and corresponding quantification. (D) RT-qPCR analysis of mRNA levels of Col1A, Fn1.

797 Results were expressed relative to Cont-SMC and expressed as mean \pm SEM (ns, Mann-

798 Whitney test). (E) Representative immunofluorescent staining of human FN (purple) and


799 phalloidin staining of actin fibers (green) in Cont- and KD-SMC (top images). Isolated FN

800 staining is also shown (white, bottom images). SMC were seeded on human FN-coated

801 surface. Quantification of FN has been made cell by cell (each dot represents a cell, n=4

802 independent experiments). (Results were expressed relative to Cont-SMC and presented as

803 mean \pm SEM; * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$; Mann-Whitney test).



804

805 **Figure 6. CTSO depletion in VSMC modulates contractile phenotype marker expression**

806 **and contraction. (A-B),** RT-qPCR analysis of mRNA levels of the SMC marker genes

807 *Acta2*, *Myh11*, *Tagln*, *Cnn1* (**A**); and *Bmp4* and *Ctso* (**B**) in Cont- and KD-SMC. Results

808 were expressed relative to Cont-SMC and expressed as mean \pm SEM; * $p < 0.05$, ** $p < 0.01$,


809 *** $p < 0.001$; Mann-Whitney test). (**C**) Representative images of Cont-SMC- and KD-SMC-

810 seeded collagen gels 48 h after release with and without U46619 and quantification of

811 U46619-induced gel contraction in Cont- and KD-SMC. (Data are expressed as mean \pm SEM;

812 * $p < 0.05$; Mann-Whitney test).

813



814

815 **Figure 7. Effect of CTSO depletion and CTSO variant expression on cell stiffness and**
 816 **FN expression. (A)** Atomic force microscopy determination of the elastic modulus of Cont-
 817 and KD-SMC, in the absence and presence of exogenous CTSO (200 ng/ml) (left), and their
 818 respective decellularized extracellular matrix (right). (Data are expressed as mean \pm SEM;
 819 **** $p < 0.0001$; one-way ANOVA). **(B)** Representative western blots and quantification of
 820 CTSO protein expression measured in cell lysate and culture medium of NIH3T3 expressing
 821 WT-CTSO, p.Ala43Val-CTSO and p.Val316Ile-CTSO. **(C)** Representative western blots and
 822 quantification of FN and Col-1 expression measured in WT-CTSO, p.Ala43Val-CTSO and
 823 p.Val316Ile-CTSO. (Data are expressed as mean \pm SEM; ** $p < 0.01$ and **** $p < 0.0001$; one-
 824 way ANOVA)

825 Tables

826

827 **Table 1. Rare functional variants in *CTSO* shared by all IA-affected subjects in families**
828 **A and B.**

Family	Genomic position (GRCh37/hg19)	Gene	Nucleotide consequence	Protein consequence	MAF (NFE in gnomAD)	Predicted Functional Impact		Cases / Total	
						SIFT	Polyphen 2	Affected	Unaffected
A	4:156847208	<i>CTSO</i>	c.946G>A	p.Val316Ile	$1.7 \cdot 10^{-5}$	Deleterious	Probably damaging	6/6	8/19
B	4:156874872	<i>CTSO</i>	c.128C>T	p.Ala43Val	$3.0 \cdot 10^{-4}$	Tolerated	Probably damaging	3/3	0/5

829 Mutation names are based on Ensembl *CTSO* transcript ENST00000433477.3. MAF: Minor

830 Allele Frequency; NFE: Exome Aggregation Consortium (Non-Finnish Europeans);

831 GnomAD: genome Aggregation Database; GERP: Genomic Evolutionary Rate Profiling;

832 SIFT: Sorting Intolerant From Tolerant.

833

834 **Table 2. Clinical characteristics, treatments and exposition to risk factors for IA cases**
 835 **and unaffected relatives according to *CTSO* status.**

	CTSO variants IA	CTSO variants no IA	No CTSO variant no IA	P-value
n	9	8	16	-
Age (yr) [median (range)]	69 (51 - 93)	60 (38 - 89)	49 (33 - 76)	-
Female	8 (88.9%)	3 (37.5%)	9 (56.3%)	0.088
Smoker or former smoker	4 (44.4%)	5 (62.5%)	8 (50%)	0.816
Alcohol intake > 150 g per week	4 (44.4%)	1 (12.5%)	3 (18.8%)	0.326
High Blood Pressure	5 (55.6%)	2 (25%)	1 (6.3%)	0.013
Dyslipemia or diabetes	2 (22.2%)	2 (25%)	0 (0%)	0.080
Antiplatelet treatment	2 (22.2%)	1 (12.5%)	1 (6.3%)	0.666
Anti-inflammatory drugs	0 (0%)	0 (0%)	1 (6.3%)	1.000
Statin treatment	1 (11.1%)	1 (12.5%)	1 (6.3%)	1.000
Oral anticoagulant treatment	1 (11.1%)	2 (25%)	4 (25%)	0.745

836 Data are expressed as median, (minimum, and maximum) for age and as count (and
 837 percentage) for all other categorical variables. The Fischer exact probability test was used for
 838 contingency comparison between groups.

839

840